{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:11:20Z","timestamp":1787886680924,"version":"build-2784847793"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2021-01715"],"award-info":[{"award-number":["2021-01715"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2021-01715"],"award-info":[{"award-number":["2021-01715"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2021-01715"],"award-info":[{"award-number":["2021-01715"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Stockholm","award":["20200431"],"award-info":[{"award-number":["20200431"]}]},{"name":"Region Stockholm","award":["20200431"],"award-info":[{"award-number":["20200431"]}]},{"name":"Region Stockholm","award":["20200431"],"award-info":[{"award-number":["20200431"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Opioid overdoses are a growing concern, particularly among people who inject drugs. Sweden, with a comparatively high proportion of drug-related mortality, introduced its first Take-Home Naloxone (THN) program in 2018, at the Stockholm needle and syringe program (NSP). In this study we compare THN participant characteristics regarding refills and overdose reversals as well as investigate predictors associated with number of reversals. We also investigate interventions performed in overdose situations and endpoints for naloxone doses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a prospective open inclusion cohort study conducted between January 24<jats:sup>th<\/jats:sup> 2018 and March 31<jats:sup>st<\/jats:sup> 2022 at the Stockholm NSP. Participants received THN, free of charge, after a training session and provided data regarding drug use and overdose experiences. During refill visits, participants reported if the naloxone was used for overdose reversal and, if so, responded to a ten-item questionnaire which included stating whether the naloxone recipient was the participant themselves or somebody else. Questionnaire data was combined with NSP database demographic data. Zero-inflated Poisson regression was applied to analyse predictors for number of reported overdose reversals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among study participants (<jats:italic>n<\/jats:italic>\u2009=\u20091,295), 66.5% stated opioids as their primary drug, and 61.4% and 81.0% had previous experience of a personal or witnessed overdose, respectively. Overall, 44.0% of participants reported a total of 1,625 overdose reversals and the victim was known to have survived in 95.6% of cases. Stimulant use (aIRR 1.26; 95% CI 1.01, 1.58), benzodiazepine use (aIRR 1.75; 95% CI 1.1, 2.78) and homelessness (aIRR 1.35; 95% CI 1.06, 1.73) were predictors associated with an increased number of reported overdose reversals. Mortality was higher among those who reported at least one overdose reversal (HR 3.4; 95% CI 2.2, 5.2).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>An NSP\u2019s existent framework can be utilised to effectively implement a THN program, provide basic training and reach numerous high-risk individuals. During the four-year study, THN participants reversed a sizeable number of potentially fatal overdoses, of which many were reported by participants whose primary drug was not opioids. Naloxone refill rate was high, indicating that participants were motivated to maintain a supply of naloxone in case of future overdose events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13011-023-00533-2","type":"journal-article","created":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T04:02:14Z","timestamp":1682136134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sweden\u2019s first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals"],"prefix":"10.1186","volume":"18","author":[{"given":"Elin","family":"Holm\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Warnqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00e5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,22]]},"reference":[{"key":"533_CR1","volume-title":"Provisional Drug Overdose Death Counts National Center for Health Statistics","author":"F Ahmad","year":"2022","unstructured":"Ahmad F, Cisewski J, Rossen L, Sutton P. Provisional Drug Overdose Death Counts National Center for Health Statistics. 2022. Available from: https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"key":"533_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.drugpo.2017.05.050","volume":"46","author":"L Beletsky","year":"2017","unstructured":"Beletsky L, Davis CS. Today\u2019s fentanyl crisis: Prohibition\u2019s Iron Law, revisited. Int J Drug Policy. 2017;46:156\u20139.","journal-title":"Int J Drug Policy"},{"key":"533_CR3","volume-title":"European Drug Report 2020 Trends and Developments","author":"The European Monitoring Centre for Drugs and Drug Addiction","year":"2020","unstructured":"The European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2020 Trends and Developments. Luxembourg: Publications Office of the European Union; 2020."},{"key":"533_CR4","volume-title":"Deaths due to \u00edntoxications from prescribed and illegal substances (D\u00f6dsfall till f\u00f6ljd av\u00a0l\u00e4kemedels- och narkotikaf\u00f6rgiftningar)","author":"The National Board of Health and Welfare, (Socialstyrelsen)","year":"2022","unstructured":"The National Board of Health and Welfare, (Socialstyrelsen). Deaths due to \u00edntoxications from prescribed and illegal substances (D\u00f6dsfall till f\u00f6ljd av\u00a0l\u00e4kemedels- och narkotikaf\u00f6rgiftningar). 2022. Available from: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/statistik\/2022-6-7915.pdf."},{"key":"533_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2019.07.030","volume":"73","author":"S Colledge","year":"2019","unstructured":"Colledge S, Peacock A, Leung J, Larney S, Grebely J, Hickman M, et al. The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. Int J Drug Policy. 2019;73:172\u201384.","journal-title":"Int J Drug Policy"},{"key":"533_CR6","doi-asserted-by":"publisher","first-page":"107714","DOI":"10.1016\/j.drugalcdep.2019.107714","volume":"206","author":"B Thylstrup","year":"2020","unstructured":"Thylstrup B, Seid AK, Tjagvad C, Hesse M. Incidence and predictors of drug overdoses among a cohort of >10,000 patients treated for substance use disorder. Drug Alcohol Depend. 2020;206:107714.","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"533_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1046\/j.1360-0443.2002.00132.x","volume":"97","author":"M Warner-Smith","year":"2002","unstructured":"Warner-Smith M, Darke S, Day C. Morbidity associated with non-fatal heroin overdose. Addiction. 2002;97(8):963\u20137.","journal-title":"Addiction"},{"key":"533_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.drugalcdep.2016.02.024","volume":"162","author":"A Caudarella","year":"2016","unstructured":"Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016;162:51\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"533_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1465-3362.2009.00057.x","volume":"28","author":"MA Stoov\u00e9","year":"2009","unstructured":"Stoov\u00e9 MA, Dietze PM, Jolley D. Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Rev. 2009;28(4):347\u201352.","journal-title":"Drug Alcohol Rev"},{"issue":"10","key":"533_CR10","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/add.13027","volume":"110","author":"J Neale","year":"2015","unstructured":"Neale J, Strang J. Naloxone\u2013does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin\/opioid overdose. Addiction. 2015;110(10):1644\u201352.","journal-title":"Addiction"},{"issue":"11","key":"533_CR11","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.2105\/AJPH.2015.302843a","volume":"105","author":"SS Martins","year":"2015","unstructured":"Martins SS, Sampson L, Cerd\u00e1 M, Galea S. Worldwide Prevalence and Trends in Unintentional Drug Overdose: A Systematic Review of the Literature. Am J Public Health. 2015;105(11):2373.","journal-title":"Am J Public Health"},{"issue":"29-31","key":"533_CR12","first-page":"1340","volume":"110","author":"A H\u00e5kansson","year":"2013","unstructured":"H\u00e5kansson A, Vedin A, Wallin C, Kral AH. Distribution of naloxone to prevent death from heroin overdose. Study of opioid dependent patients\u2019 attitudes to be part of the antidote program. Lakartidningen. 2013;110(29\u201331):1340\u20132.","journal-title":"Lakartidningen."},{"issue":"9","key":"533_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/add.13429","volume":"111","author":"S Darke","year":"2016","unstructured":"Darke S, Duflou J. The toxicology of heroin-related death: estimating survival times. Addiction. 2016;111(9):1607\u201313.","journal-title":"Addiction"},{"key":"533_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.drugalcdep.2017.05.001","volume":"178","author":"R McDonald","year":"2017","unstructured":"McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation. Drug Alcohol Depend. 2017;178:176\u201387.","journal-title":"Drug Alcohol Depend"},{"key":"533_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.drugalcdep.2014.12.009","volume":"148","author":"E Behar","year":"2015","unstructured":"Behar E, Santos GM, Wheeler E, Rowe C, Coffin PO. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend. 2015;148:209\u201312.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"533_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1360-0443.2008.02182.x","volume":"103","author":"TC Green","year":"2008","unstructured":"Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction. 2008;103(6):979\u201389.","journal-title":"Addiction"},{"issue":"1","key":"533_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.drugpo.2013.05.006","volume":"25","author":"JD Jones","year":"2014","unstructured":"Jones JD, Roux P, Stancliff S, Matthews W, Comer SD. Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users. Int J Drug Policy. 2014;25(1):166\u201370.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"533_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","volume":"8","author":"AK Clark","year":"2014","unstructured":"Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153\u201363.","journal-title":"J Addict Med"},{"key":"533_CR19","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"issue":"5","key":"533_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11904-017-0363-y","volume":"14","author":"MC Kennedy","year":"2017","unstructured":"Kennedy MC, Karamouzian M, Kerr T. Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review. Curr HIV\/AIDS Rep. 2017;14(5):161\u201383.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"533_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","volume":"158","author":"PO Coffin","year":"2013","unstructured":"Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1\u20139.","journal-title":"Ann Intern Med"},{"issue":"8","key":"533_CR22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/add.12961","volume":"110","author":"C Rowe","year":"2015","unstructured":"Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin PO. Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program. Addiction. 2015;110(8):1301\u201310.","journal-title":"Addiction"},{"issue":"2","key":"533_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/ADM.0000000000000461","volume":"13","author":"JG Katzman","year":"2019","unstructured":"Katzman JG, Greenberg NH, Takeda MY, Moya BM. Characteristics of Patients With Opioid Use Disorder Associated With Performing Overdose Reversals in the Community: An Opioid Treatment Program Analysis. J Addict Med. 2019;13(2):131\u20138.","journal-title":"J Addict Med"},{"key":"533_CR24","doi-asserted-by":"publisher","first-page":"811001","DOI":"10.3389\/fpubh.2022.811001","volume":"10","author":"K Troberg","year":"2022","unstructured":"Troberg K, Isendahl P, Blom\u00e9 MA, Dahlman D, H\u00e5kansson A. Characteristics of and Experience Among People Who Use Take-Home Naloxone in Sk\u00e5ne County. Sweden Front Public Health. 2022;10:811001.","journal-title":"Sweden Front Public Health"},{"issue":"1","key":"533_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12954-022-00647-z","volume":"19","author":"D Eide","year":"2022","unstructured":"Eide D, Lobmaier P, Clausen T. Who is using take-home naloxone? An examination of supersavers. Harm Reduct J. 2022;19(1):65.","journal-title":"Harm Reduct J"},{"issue":"1","key":"533_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12888-020-2470-3","volume":"20","author":"K Troberg","year":"2020","unstructured":"Troberg K, Isendahl P, Blome MA, Dahlman D, Hakansson A. Protocol for a multi-site study of the effects of overdose prevention education with naloxone distribution program in Skane County, Sweden. BMC Psychiatry. 2020;20(1):49.","journal-title":"BMC Psychiatry"},{"key":"533_CR27","volume-title":"Misuse substance related diagnoses and gambling (Missbruk,\u00a0substansrelaterade\u00a0diagnoser och spel om\u00a0pengar)","author":"The Swedish National Board of Health and Welfare, (Socialstyrelsen)","year":"2021","unstructured":"The Swedish National Board of Health and Welfare, (Socialstyrelsen). Misuse substance related diagnoses and gambling (Missbruk,\u00a0substansrelaterade\u00a0diagnoser och spel om\u00a0pengar). 2021. Available from: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/ovrigt\/2021-4-7277.pdf."},{"key":"533_CR28","volume-title":"National Overdose Strategy 2014\u20132017 Oslo, Norway","author":"Norwegian Directorate at Health","year":"2014","unstructured":"Norwegian Directorate at Health. National Overdose Strategy 2014\u20132017 Oslo, Norway. 2014. Available from: https:\/\/www.regjeringen.no\/contentassets\/405ff92c06e34a9e93e92149ad616806\/20190320_nasjonal_overdosestrategi_2019-2022.pdf."},{"key":"533_CR29","unstructured":"The National Board of Health and Welfare (Socialstyrelsen). Making naloxone available for patients and individuals outside of healthcare. Opportunities within the current legislation (Tillg\u00e4ngligg\u00f6ra naloxon f\u00f6r patienter och personer utanf\u00f6r h\u00e4lso- och sjukv\u00e5rden \u2013 M\u00f6jligheter inom ramen f\u00f6r dagens r\u00e4ttsliga regleringar). 2017. Available from: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/ovrigt\/2017-6-6.pdf."},{"key":"533_CR30","volume-title":"Information material on Naloxone (Informationsmaterial om naloxon)","author":"The National Board of Health and Welfare (Socialstyrelsen)","year":"2019","unstructured":"The National Board of Health and Welfare (Socialstyrelsen). Information material on Naloxone (Informationsmaterial om naloxon). 2019. Available from: https:\/\/www.socialstyrelsen.se\/kunskapsstod-och-regler\/omraden\/missbruk-och-beroende\/material-om-naloxon\/."},{"key":"533_CR31","volume-title":"Preventing opioid overdose deaths with take-home naloxone","author":"J Strang","year":"2016","unstructured":"Strang J, McDonald R, Hedrich D, Simon R. Preventing opioid overdose deaths with take-home naloxone. Luxembourg: Publications Office of the European Union; 2016."},{"issue":"5","key":"533_CR32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/23744235.2020.1727002","volume":"52","author":"M K\u00e5berg","year":"2020","unstructured":"K\u00e5berg M, Karlsson N, Discacciati A, Widgren K, Weiland O, Ekstr\u00f6m AM, et al. Significant decrease in injection risk behaviours among participants in a needle exchange programme. Infect Dis (Lond). 2020;52(5):336\u201346.","journal-title":"Infect Dis (Lond)"},{"key":"533_CR33","volume-title":"Opioid overdoses and overdose prevention: The establishment of take-home naloxone in Norway","author":"D Madah-Amiri","year":"2017","unstructured":"Madah-Amiri D. Opioid overdoses and overdose prevention: The establishment of take-home naloxone in Norway. 2017."},{"key":"533_CR34","doi-asserted-by":"publisher","first-page":"109645","DOI":"10.1016\/j.drugalcdep.2022.109645","volume":"240","author":"\u00d8B Ericson","year":"2022","unstructured":"Ericson \u00d8B, Eide D, Lobmaier P, Clausen T. Risks and overdose responses: Participant characteristics from the first seven years of a national take-home naloxone program. Drug Alcohol Depend. 2022;240:109645.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"533_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/02791072.2018.1430409","volume":"50","author":"AS Bennett","year":"2018","unstructured":"Bennett AS, Bell A, Doe-Simkins M, Elliott L, Pouget E, Davis C. From Peers to Lay Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh. PA J Psychoactive Drugs. 2018;50(3):240\u20136.","journal-title":"PA J Psychoactive Drugs"},{"issue":"6","key":"533_CR36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s11524-010-9495-8","volume":"87","author":"L Enteen","year":"2010","unstructured":"Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health. 2010;87(6):931\u201341.","journal-title":"J Urban Health"},{"key":"533_CR37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1471-2458-14-297","volume":"14","author":"M Doe-Simkins","year":"2014","unstructured":"Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, Hackman H, Ozonoff A, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014;14:297.","journal-title":"BMC Public Health"},{"issue":"6","key":"533_CR38","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s11524-011-9600-7","volume":"88","author":"AS Bennett","year":"2011","unstructured":"Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County. Pennsylvania J Urban Health. 2011;88(6):1020\u201330.","journal-title":"Pennsylvania J Urban Health"},{"issue":"3","key":"533_CR39","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.9778\/cmajo.20140008","volume":"2","author":"O Banjo","year":"2014","unstructured":"Banjo O, Tzemis D, Al-Qutub D, Amlani A, Kesselring S, Buxton JA. A quantitative and qualitative evaluation of the British Columbia Take Home Naloxone program. CMAJ Open. 2014;2(3):E153\u201361.","journal-title":"CMAJ Open"},{"key":"533_CR40","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.drugalcdep.2016.02.031","volume":"162","author":"A McAuley","year":"2016","unstructured":"McAuley A, Munro A, Bird SM, Hutchinson SJ, Goldberg DJ, Taylor A. Engagement in a National Naloxone Programme among people who inject drugs. Drug Alcohol Depend. 2016;162:236\u201340.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"533_CR41","doi-asserted-by":"publisher","first-page":"e0230127","DOI":"10.1371\/journal.pone.0230127","volume":"15","author":"M Buresh","year":"2020","unstructured":"Buresh M, Gicquelais RE, Astemborski J, Kirk GD, Mehta SH, Genberg BL. Fatal overdose prevention and experience with naloxone: A cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland. PLoS ONE. 2020;15(3):e0230127.","journal-title":"PLoS ONE"},{"key":"533_CR42","doi-asserted-by":"publisher","first-page":"103253","DOI":"10.1016\/j.drugpo.2021.103253","volume":"95","author":"R McDonald","year":"2021","unstructured":"McDonald R, Parkin S, Eide D, Neale J, Clausen T, Metrebian N, et al. Rethinking \u2018carriage\u2019 of take-home naloxone. Int J Drug Policy. 2021;95:103253.","journal-title":"Int J Drug Policy"},{"key":"533_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jsat.2017.10.008","volume":"84","author":"SR Kenney","year":"2018","unstructured":"Kenney SR, Anderson BJ, Bailey GL, Stein MD. Factors associated with naloxone administration in an opioid dependent sample. J Subst Abuse Treat. 2018;84:17\u201320.","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"533_CR44","doi-asserted-by":"publisher","first-page":"e0224686","DOI":"10.1371\/journal.pone.0224686","volume":"14","author":"L Dayton","year":"2019","unstructured":"Dayton L, Gicquelais RE, Tobin K, Davey-Rothwell M, Falade-Nwulia O, Kong X, et al. More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD. PLoS ONE. 2019;14(11):e0224686.","journal-title":"PLoS ONE"},{"key":"533_CR45","doi-asserted-by":"publisher","first-page":"103512","DOI":"10.1016\/j.drugpo.2021.103512","volume":"100","author":"A McAuley","year":"2022","unstructured":"McAuley A, Matheson C, Robertson JR. From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic. Int J Drug Policy. 2022;100:103512.","journal-title":"Int J Drug Policy"},{"issue":"10","key":"533_CR46","doi-asserted-by":"publisher","first-page":"e030046","DOI":"10.1136\/bmjopen-2019-030046","volume":"9","author":"S Young","year":"2019","unstructured":"Young S, Williams S, Otterstatter M, Lee J, Buxton J. Lessons learned from ramping up a Canadian Take Home Naloxone programme during a public health emergency: a mixed-methods study. BMJ Open. 2019;9(10):e030046.","journal-title":"BMJ Open"},{"issue":"1","key":"533_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12954-020-00425-9","volume":"17","author":"M V\u00e4rm\u00e5 Falk","year":"2020","unstructured":"V\u00e4rm\u00e5 Falk M, Str\u00f6mdahl S, Ekstr\u00f6m AM, K\u00e5berg M, Karlsson N, Dahlborn H, et al. A qualitative study of facilitators and barriers to participate in a needle exchange program for women who inject drugs. Harm Reduct J. 2020;17(1):84.","journal-title":"Harm Reduct J"},{"issue":"Suppl 1","key":"533_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/jlme.12035","volume":"41","author":"C Davis","year":"2013","unstructured":"Davis C, Webb D, Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics. 2013;41(Suppl 1):33\u20136.","journal-title":"J Law Med Ethics"},{"issue":"3","key":"533_CR49","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.drugpo.2009.01.003","volume":"21","author":"KD Wagner","year":"2010","unstructured":"Wagner KD, Valente TW, Casanova M, Partovi SM, Mendenhall BM, Hundley JH, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles. CA Int J Drug Policy. 2010;21(3):186\u201393.","journal-title":"CA Int J Drug Policy"},{"issue":"4","key":"533_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1300\/J069v26n04_08","volume":"26","author":"CT Baca","year":"2007","unstructured":"Baca CT, Grant KJ. What heroin users tell us about overdose. J Addict Dis. 2007;26(4):63\u20138.","journal-title":"J Addict Dis"},{"key":"533_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drugpo.2017.09.010","volume":"50","author":"AD Latimore","year":"2017","unstructured":"Latimore AD, Bergstein RS. \u201cCaught with a body\u201d yet protected by law? Calling 911 for opioid overdose in the context of the Good Samaritan Law. Int J Drug Policy. 2017;50:82\u20139.","journal-title":"Int J Drug Policy"},{"key":"533_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.drugpo.2017.06.008","volume":"48","author":"S Koester","year":"2017","unstructured":"Koester S, Mueller SR, Raville L, Langegger S, Binswanger IA. Why are some people who have received overdose education and naloxone reticent to call Emergency Medical Services in the event of overdose? Int J Drug Policy. 2017;48:115\u201324.","journal-title":"Int J Drug Policy"},{"key":"533_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.drugpo.2019.01.006","volume":"71","author":"M Karamouzian","year":"2019","unstructured":"Karamouzian M, Kuo M, Crabtree A, Buxton JA. Correlates of seeking emergency medical help in the event of an overdose in British Columbia, Canada: Findings from the Take Home Naloxone program. Int J Drug Policy. 2019;71:157\u201363.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"533_CR54","doi-asserted-by":"publisher","first-page":"e011224","DOI":"10.1136\/bmjopen-2016-011224","volume":"6","author":"G Ambrose","year":"2016","unstructured":"Ambrose G, Amlani A, Buxton JA. Predictors of seeking emergency medical help during overdose events in a provincial naloxone distribution programme: a retrospective analysis. BMJ Open. 2016;6(6):e011224.","journal-title":"BMJ Open"},{"issue":"1","key":"533_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10900-012-9591-7","volume":"38","author":"SE Lankenau","year":"2013","unstructured":"Lankenau SE, Wagner KD, Silva K, Kecojevic A, Iverson E, McNeely M, et al. Injection drug users trained by overdose prevention programs: responses to witnessed overdoses. J Community Health. 2013;38(1):133\u201341.","journal-title":"J Community Health"},{"key":"533_CR56","doi-asserted-by":"publisher","first-page":"102663","DOI":"10.1016\/j.drugpo.2020.102663","volume":"77","author":"KMA Trayner","year":"2020","unstructured":"Trayner KMA, McAuley A, Palmateer NE, Goldberg DJ, Shepherd SJ, Gunson RN, et al. Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs. Int J Drug Policy. 2020;77:102663.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"533_CR57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2471\/BLT.12.108282","volume":"91","author":"BM Mathers","year":"2013","unstructured":"Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102\u201323.","journal-title":"Bull World Health Organ"},{"key":"533_CR58","doi-asserted-by":"publisher","first-page":"103787","DOI":"10.1016\/j.drugpo.2022.103787","volume":"107","author":"R McDonald","year":"2022","unstructured":"McDonald R, Eide D, Abel-Ollo K, Barnsdale L, Carter B, Clausen T, et al. A rapid assessment of take-home naloxone provision during COVID-19 in Europe. Int J Drug Policy. 2022;107:103787.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"533_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12954-021-00499-z","volume":"18","author":"K Lindqvist","year":"2021","unstructured":"Lindqvist K, Wallmofeldt C, Holm\u00e9n E, Hammarberg A, K\u00e5berg M. Health literacy and changes in pattern of drug use among participants at the Stockholm Needle Exchange Program during the COVID-19 pandemic. Harm Reduct J. 2021;18(1):52.","journal-title":"Harm Reduct J"},{"key":"533_CR60","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.drugalcdep.2017.06.029","volume":"179","author":"A Siegler","year":"2017","unstructured":"Siegler A, Huxley-Reicher Z, Maldjian L, Jordan R, Oliver C, Jakubowski A, et al. Naloxone use among overdose prevention trainees in New York City: A longitudinal cohort study. Drug Alcohol Depend. 2017;179:124\u201330.","journal-title":"Drug Alcohol Depend"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-023-00533-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-023-00533-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-023-00533-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T05:03:52Z","timestamp":1682139832000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-023-00533-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,22]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1186\/s13011-023-00533-2","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,22]]},"assertion":[{"value":"22 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Helsinki declaration and was approved by The Regional Ethical Review Board in Stockholm (Dnr: 2013\/495\u201331\/3, 2015\/1374\u201332 and 2020\u201303325). Ethical approval included usage of research data from the quality register InfCare NSP. No additional informed consent was needed from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MK has received honoraria for lectures\/consultancy from AbbVie, Gilead, MSD, Mundipharma, DnE Pharma and Nordic Drugs and has received research grants from Gilead and Nordic Drugs.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}